You know there’s money to be made in the global generic drug market.

But which countries are up, which are down and which are coming into their own? Which companies are working together, who’s suing whom and how could developments inside top industry players affect expansion for makers of generics and biologics?

Here are the answers you need today to identify the best —and safest — business prospects for the years ahead.

OrderToday

With original research, country-by-country comparisons and five-year market forecasts, this two-volume report gives you the power to identify — and seize — the best expansion opportunities around the globe.

Profiles of 12 countries and 27 leading generics and biologics companies

Companies. Volume I reveals the financial status, products and recent developments of players such as Actavis, Dr. Reddy’s, Hospira, Sanofi and Watson. It also analyzes the impact of global developments, including the FDA’s new user fee program, trends in EMA inspections, consolidations, M&As, patent actions and the imminent patent cliff.

Countries.Volume II takes you inside the generic drug markets of 12 countries. Make country-by-country comparisons — market size, product approvals, the regulatory environment, pricing and reimbursement, manufacturing capabilities and intellectual property policies.

Decision Support. You also get FREE online access to Espicom Interactive for full-text, cross-file searching, presentation-ready tables and graphics, a report-building tool, and instant translation into nine languages.

Buy now for instant access to the hard-to-find data, trends and analysis it takes to make the right decisions about global expansion, including:

• Five-year market forecasts — overall and for individual-country markets
• What branded companies are taking an interest in generics
• How the latest regulatory developments shape prospects for biologics expansion
• How the global recession is affecting specific countries and drugmakers
• Two opposing trends being driven by the economic downturn — and how they change expansion prospects
• What companies are involved in legal challenges and litigation

In the decades-long tradition of Espicom research and analysis, the World Generic Market Report 2012 brings you ready-to-use statistics, primary source data, original research, insightful commentary and practical analysis available from no other single resource. There is no smarter starting point for identifying the best and safest business prospects among the global generic drug and biologics industry players.

Buy Now
The World Generic Market Report 2012 is offered by FDAnews in print or PDF formats for $1,390.

Satisfaction Guaranteed
There's no risk when you purchase from FDAnews with our money-back guarantee. Not satisfied with your publication? Return the hard copy within 30 days (in resalable condition), and we will refund 100 percent of your purchase price (less shipping/handling). For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase to receive a refund.